• The US FDA has proposed removing semaglutide, tirzepatide, and liraglutide from federal compounding exemptions.
• The proposal would limit pharmacies from compounding versions of these GLP-1 medicines when approved products are available.
• This move directly affects Novo Nordisk’s GLP-1 portfolio, including its branded diabetes and obesity drugs under ticker NYSE:NVO.

Novo Nordisk, traded as NYSE:NVO, is a major player in diabetes and obesity treatments, with GLP-1 therapies at the center of its product lineup. The FDA’s proposal focuses on restricting compounded copies of GLP-1 drugs built on semaglutide, tirzepatide, and liraglutide, which are core ingredients in some of the company’s best known therapies.

For investors, the proposal is worth tracking because it relates to product exclusivity and protection of branded GLP-1 drugs. If the rulemaking advances, it could influence how much competition Novo Nordisk faces from compounded alternatives and how tightly its intellectual property and regulatory protections are enforced in the US market.

Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.

The FDA’s proposal to remove semaglutide, tirzepatide, and liraglutide from federal compounding exemptions directly targets a source of lower cost, non‑branded competition to approved GLP‑1 products. For Novo Nordisk, which relies heavily on GLP‑1 drugs for diabetes and obesity, fewer compounded copies could help keep more prescription volume within its approved brands instead of flowing to pharmacies that mix their own versions from bulk ingredients. The agency also framed the move as support for the integrity of the drug approval process, which tends to favor companies that have invested heavily in clinical trials and regulatory work.

Operationally, the proposal may reduce pricing pressure from compounded alternatives that can undercut list prices, especially in self‑pay or under‑insured segments. However, it does not address other sources of competition such as biosimilars, potential price cuts, or rival GLP‑1 offerings from companies like Eli Lilly and Pfizer. Investors will likely focus on how quickly the proposal progresses, what final form the rule takes, and whether there are carve outs for specific clinical settings that still allow some compounding activity.

The Risks and Rewards Investors Should Consider

• ⚠️ The company already faces pricing pressure in GLP‑1 therapies, and regulatory changes do not remove broader reimbursement or discounting risks.
• ⚠️ Analysts have highlighted a high level of debt and dividends that are not fully covered by free cash flow, which can limit flexibility if competition intensifies.
• 🎁 GLP‑1 drugs are a core earnings driver, and reduced competition from compounded versions could support the role of approved brands in this category.
• 🎁 Simply Wall St’s checks indicate Novo Nordisk trades at good value compared with peers and the wider pharmaceuticals industry, while earnings grew by 1.4% over the past year.

What To Watch Going Forward

From here, keep an eye on the FDA’s rulemaking timeline, including public comment and any revisions before a final decision. Watch how much compounded GLP‑1 volume actually shifts back to branded products and whether payers adjust coverage, prior authorization rules, or rebates in response. It is also worth tracking competitor moves, especially from Eli Lilly in GLP‑1 weight management, and any updates on pricing for Novo Nordisk’s US portfolio, given plans for lower list prices in 2027. Together, these factors will shape how much of the regulatory benefit translates into real world sales and cash flows for NYSE:NVO.

To ensure you're always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.